Creative Biolabs Releases Effective Cell Therapies for CAR-T, TCR-T and Dendritic Cells

New York, May 27, 2019 Creative Biolabs, a rising biotech company specialized in cancer cell therapy, now releases CAR-T Therapy, TCR-T Therapy, dendritic cell therapy to best suit different requirements of global clients.


1 One-Stop CAR-T Therapy Development

Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising with a remarkable ability to eliminate multiple tumors. Equipped with a complete collection of CAR products of different generations targeting various biomarkers, Creative Biolabs offers high-quality custom service covering the entire CAR-T therapy development process, which includes but are not limited to Biomarker Identification & Selection, High Affinity ScFv Generation, CAR Design & Construction, Virus Packaging & CAR Gene Delivery, CAR-T In Vitro Assay, CAR-T Preclinical In Vivo Assay, CAR-T Clinical Trail. Besides, a large collection of CD19-targeted CAR-T cells are also available in Creative Biolabs.


2 TCR Modified T Cell Development

T cells with gene-engineered T cell receptor (TCR) have been proven as a feasible and therapeutic potential tool for cancer treatment. In order to meet the increasing needs of TCR development, Creative Biolabs offers one-stop TCR-T therapy development services including the identification and selection of TCR biomarker, TCR generation and optimization, TCR design and construction, TCR gene packaging and delivery, TCR in vitro or in vivo assay. Additionally, an exclusive line of ready-to-use TCR-T cell construction products are provided, such as virus packaging, purification, expansion and titer determination kits.


3 Dendritic Cell Vaccine Development

To enhance the efficacy of in vitro activation of DCs and accurately stimulate the patient’s immune system, Creative Biolabs generates potent DCs and develop DC vaccines based on autologous DCs, activated by a proprietary ex vivo maturation process. The DCs engineered in Creative Biolabs not only raise specific anti-tumor immune response but also recruit and stimulate unique NK cells. Meanwhile, they are capable of producing plenty of key chemokines to attract other immune cells and contributing to combined activation of T-helper cells and stimulation of higher numbers of killer T-cells. Notably, these potent DCs can be manufactured in just three days based on a comprehensive dendritic cell therapy platform.

Empowered by first-class platforms and rich experience in the field of antibody discovery and immunotherapy, Creative Biolabs can promise timely troubleshooting to guarantee the highest success rate of each project. More detailed information on the above mentioned services or another customized plan can be reached at




As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.


Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States